Granted Patent B2

US 12,685,722 · App. 19/431,440 · Granted Jul 21, 2026

Inventors: Christopher G Witowski (Tampa, FL); Jacqueline L. Salm (Tampa, FL)

Assignee: Atai Therapeutics, Inc.

A61K31/4045A61K9/0043A61K9/06A61K9/2009A61K9/2013A61K9/2018A61K9/2027A61K9/2054A61K9/7061A61K9/7069A61K31/405A61K31/48A61K31/55A61K31/675C07D209/16

Abstract

Claims (24)

1 . A method of treating bipolar II disorder in a subject in need thereof, the method comprising mucosally administering to the subject:

a therapeutically effective amount of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof,

wherein the mucosal administration provides absorption of the 5-MeO-DMT into the blood of the subject after administration.

2 . The method of claim 1 , wherein the mucosal administration is sublingual, buccal, nasal, inhalation, or oral.

3 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a strip, a solution, a suspension, a gel, a liquid, an emulsion, liposomes, microparticles, a film, a powder, or a patch.

4 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a spray.

5 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a film.

6 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a strip.

7 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a solution.

8 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a suspension.

9 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a gel.

10 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a liquid.

11 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a sublingual strip.

12 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of microparticles.

13 . The method of claim 1 , wherein the 5-MeO-DMT is administered in the form of a pharmaceutical composition comprising 5-MeO-DMT and a pharmaceutically acceptable carrier.

14 . The method of claim 1 , wherein the mucosal administration comprises administration to the nasal mucosa, lung mucosa, gastric mucosa, esophageal mucosa, or intestinal mucosa.

15 . The method of claim 14 , wherein about 5 mg to about 25 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.

16 . The method of claim 15 , wherein about 6 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.

17 . The method of claim 15 , wherein about 8 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.

18 . The method of claim 15 , wherein about 12 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.

19 . The method of claim 15 , wherein about 18 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered to the subject.

20 . The method of claim 16 , wherein the method further comprises subsequently administering about 12 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to the subject.

21 . The method of claim 18 , wherein the method further comprises subsequently administering about 18 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to the subject.

22 . The method of claim 20 , wherein the method further comprises subsequently administering about 18 mg of 5-MeO-DMT or a pharmaceutically acceptable salt thereof to the subject.

Assignments (4)

Continuity (9)

References Cited (400)